The imminent cash runway and September 10 debt payment create a binary near-term catalyst: either the company secures financing or strategic alternatives (including potential sale) before the liquidity covenant breach, or it faces default. The August sNDA submission for myelofibrosis is a positive pipeline catalyst but does not resolve the near-term liquidity crisis. Traders should watch for financing announcements, potential equity dilution, or a strategic transaction in the coming weeks.
Price Chart
Executive Summary
Karyopharm reported Q2 2026 total revenue of $33.4M, down 12% YoY from $37.9M, driven by a $5.6M decline in license and other revenue. The company reaffirmed full-year 2026 guidance of $130M-$150M total revenue and remains on track for an August sNDA submission for selinexor in myelofibrosis under the Accelerated Approval pathway. Critically, the company disclosed it expects cash to fund operations only into September 2026 and is actively evaluating financing or strategic alternatives, with a $15.8M debt payment due September 10 that could trigger a liquidity covenant default.
Key Financial Metrics
Key Facts
- Total revenue declined 12% YoY to $33.4M from $37.9M
- Net loss widened to $67.0M from $37.3M YoY, driven by $32.1M in non-cash other expense
- Cash, cash equivalents and investments totaled $65.4M as of June 30, 2026
- Company expects existing liquidity to fund operations only into September 2026
- $15.8M principal payment due September 10, 2026; payment without financing would breach $10M minimum liquidity covenant
- Company is actively evaluating financing opportunities and strategic alternatives with Centerview Partners
- Phase 3 XPORT-EC-042 endometrial cancer trial did not meet its primary endpoint of PFS
- Planned August sNDA submission for selinexor in myelofibrosis under Accelerated Approval remains on track
- Full-year 2026 total revenue guidance reaffirmed at $130M-$150M
Financial Impact
Cash runway extends only into September 2026 with a $15.8M debt payment due September 10 that risks a liquidity covenant breach; net loss of $67.0M in Q2 vs $37.3M in Q2 2025
Risk Factors
- Liquidity covenant breach on September 10 if no financing or waiver obtained
- Potential for highly dilutive equity financing given $48M market cap
- Endometrial cancer trial failure removes a key pipeline value driver
- Going concern risk if financing not secured
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347897 |
| Document: kpti-20260813.htm | 0001193125-26-347897 |
| Document: 0001193125-26-347897-index-headers.html | 0001193125-26-347897 |
| Document: 0001193125-26-347897-index.html | 0001193125-26-347897 |
| Document: 0001193125-26-347897.txt | 0001193125-26-347897 |
| 8-K Data (Synthetic) | 0001193125-26-347897 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access